Ossipov M. H., Zhang E. T., Carvajal C., Gardell L., Quirion R., Dumont Y., Lai J., Porreca F. (2002). Selective mediation of nerve injury-induced tactile hypersensitivity by neuropeptide Y, J Neurosci, 22(22), 9858-67.

Panisset M., Gauthier S., Moessler H., Windisch M. (2002). Cerebrolysin in Alzheimer's disease: a randomized, double-blind, placebo-controlled trial with a neurotrophic agent, J Neural Transm, 109(7-8), 1089-104.

Poirier J. (2002). Cholesterol transport and synthesis are compromised in the brain in sporadic Alzheimer's Disease: From risk factors to therapeutic targets . Dans Gauthier S. & Cummings J. L. (Éds.) , Alzheimer's Disease and Related Disorders Annual (pp. 1-23). Martin Dunitz Ltd.

Poirier J. (2002). High blood pressure and apolipoprotein E4: A true synergistic effect on late life cognitive function, Stroke, 32, 2888-2889.

Poirier J. (2002). Evidence that the clinical effects of cholinesterase inhibitors are related to potency and targeting of action, Int J Clin Pract Suppl(127), 6-19.

Poirier J., Panisset M. (2002). Apolipoprotein E: A novel therapeutic target for the treatment of Alzheimer's disease, Adv Behav Biol, 51, 39-43.

Poyner D. R., Sexton P. M., Marshall I., Smith D. M., Quirion R., Born W., Muff R., Fischer J. A., Foord S. M. (2002). International Union of Pharmacology. XXXII. The mammalian calcitonin gene-related peptides, adrenomedullin, amylin, and calcitonin receptors, Pharmacol Rev, 54(2), 233-46.

Prat A., Biernacki K., Lavoie J. F., Poirier J., Duquette P., Antel J. P. (2002). Migration of multiple sclerosis lymphocytes through brain endothelium, Arch Neurol, 59(3), 391-7.

Pruessner J., Kohler S., Crane J., Pruessner J., Lord C., Byrne A., Kabani N., Collins D. L., Evans A. C. (2002). Volumetry of temporopolar, perirhinal, entorhinal and parahippocampal cortex from high-resolution MR images: considering the variability of the collateral sulcus, Cereb Cortex, 12(12), 1342-53.

Quirion R. (2002). A Canadian experiment: the Institute of Neurosciences, Mental Health and Addiction. How to link up the brain via a virtual institute, Trends Neurosci, 25(5), 268-70.

Quirion R., Björklund A., Hökfelt T. (2002). Peptide Receptors Part II . Elsevier.

Redrobe J. P., Calo G., Regoli D., Quirion R. (2002). Nociceptin receptor antagonists display antidepressant-like properties in the mouse forced swimming test, Naunyn Schmiedebergs Arch Pharmacol, 365(2), 164-7.

Redrobe J. P., Dumont Y., Fournier A., Quirion R. (2002). The neuropeptide Y (NPY) Y1 receptor subtype mediates NPY-induced antidepressant-like activity in the mouse forced swimming test, Neuropsychopharmacology, 26(5), 615-24.

Redrobe J. P., Dumont Y., Quirion R. (2002). Neuropeptide Y (NPY) and depression: from animal studies to the human condition, Life Sci, 71(25), 2921-37.

Rockwood K., Gauthier S., Erkinjuntti T. (2002). Prevention and treatment of vascular dementia . Dans Erkunjutti T. & Gauthier S. (Éds.) , Vascular Cognitive Impairment (pp. 587-595). Martin Dunitz Ltd.

Schappert K., Sevigny P., Poirier J. (2002). Apolipoprotein E: A pharmacogenomic marker used in the treatment of Alzheimer's disease . Dans B. Lerer (Éd.) , Pharmacogenetics of psychotropic drugs (pp. 358-369). Cambridge University Press.

Seto D., Zheng W. H., McNicoll A., Collier B., Quirion R., Kar S. (2002). Insulin-like growth factor-I inhibits endogenous acetylcholine release from the rat hippocampal formation: possible involvement of GABA in mediating the effects, Neuroscience, 115(2), 603-12.

Sibley A., MacKnight C., Rockwood K., Fisk J., Gauthier S., Guzman D. A., Hogan D. B. (2002). The effect of the living situation on the severity of dementia at diagnosis, Dement Geriatr Cogn Disord, 13(1), 40-5.

Tisserand D. J., Pruessner J., Sanz Arigita E. J., van Boxtel M. P., Evans A. C., Jolles J., Uylings H. B. (2002). Regional frontal cortical volumes decrease differentially in aging: an MRI study to compare volumetric approaches and voxel-based morphometry, Neuroimage, 17(2), 657-69.

Trang T., Sutak M., Quirion R., Jhamandas K. (2002). The role of spinal neuropeptides and prostaglandins in opioid physical dependence, Br J Pharmacol, 136(1), 37-48.